A cheap steroid dramatically reduced coronavirus deaths in a 'major breakthrough' trial
- The cheap, widely available steroid dexamethasone has been found to help treat some people who are sick with a
- A major clinical trial in the UK found that the drug reduced deaths by one-third for patients on ventilators and by about 20% for those who got supplemental oxygen.
- "This is a huge breakthrough," the National
HealthService's medical director, Stephen Powis, said in a statement Tuesday.
A UK clinical trial has concluded that a cheap and widely available steroid can significantly cut deaths among coronavirus patients.
Giving the steroid dexamethasone reduced deaths by one-third for critically ill coronavirus patients who were on ventilators, the researchers found. It cut deaths by 20% among patients with
"Dexamethasone is the first drug to be shown to improve survival in COVID-19," Peter Horby, a professor of emerging infectious diseases at the University of Oxford who was one of the chief investigators for the trial, said in a statement Tuesday. "This is an extremely welcome result."
He told the BBC it was "a major breakthrough."
The researchers said the steroid should be used widely to treat coronavirus patients, based on the results of the study.
The trial, known as the Randomised Evaluation of COVID-19 Therapy, began in March. Its goal was to test a variety of possible coronavirus treatments, and it enrolled 11,500 patients in the UK. As part of the trial 2,104 patients were randomly assigned to get 6 milligrams of dexamethasone once a day for 10 days. The results of their treatment were compared with those of 4,321 patients who did not receive dexamethasone.
Researchers found that dexamethasone improved survival among patients on ventilators and patients who needed oxygen. For patients who didn't need help breathing, the steroid offered no benefit.
"This is a huge breakthrough in our search for new ways to successfully treat patients with COVID, both in the UK and across the world," the National Health Service's medical director, Stephen Powis, said in a statement. "It is thanks to NHS staff and patients who participated in the trial that from now, we are able to use this drug to dramatically improve COVID-19 survival for people in hospital who require oxygen or ventilation."
- EPFO adds a net 15.62 lakh members in Dec; 8.41 lakh new subscribers join workforce
- Zee Entertainment reaches out to Sony to revive terminated merger
- India's AI market to touch $17-billion by 2027: Nasscom-BCG report
- Worried about 'forever chemicals' in your water? Try electron-beaming it!
- Wetlands in the icy Arctic have begun releasing 9% more planet-warming methane in the past two decades: study